Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma

Jae Seung Lee1,2*, Young Eun Chon3*, Beom Kyung Kim1,2, Jun Yong Park1,2, Do Young Kim1,2, Sang Hoon Ahn1,2, Kwang-Hyun Han1,2, Wonseok Kang4, Moon Seok Choi4, Geum-Youn Gwak4, Yong-Han Paik4, Joon Hyeok Lee4, Kwang Cheol Koh4, Seung Woon Paik4, Hwi Young Kim5, Kwon Yoo5, Yeonjung Ha5, Mi Na Kim5, Joo Ho Lee5, Seong Gyu Hwang6, Soon Sun Kim6, Hye Jung Cho6, Jae Youn Cheong6, Sung Won Cho6, Seung Ha Park7, Nae-Yun Heo7, Young Mi Hong8, Ki Tae Yoon8, Mong Cho8, Jung Gil Park8, Min Kyu Kang8, Soo Young Park10, Young Oh Kweon10, Won Young Tak10, Se Young Jang10, Dong Hyun Sinn4, and Seung Up Kim1,2; The Korean TACE Study Group

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 2Yonsei Liver Center, Severance Hospital, Seoul; 3Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam; 4Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 5Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul; 6Department of Gastroenterology, Ajou University School of Medicine, Suwon; 7Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan; 8Liver Center, Pusan National University Yangsan Hospital, Yangsan; 9Department of Internal Medicine, Yeungnam University Medical Centre, Daegu; 10Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

Purpose: Alpha-fetoprotein (AFP) is a prognostic marker for hepatocellular carcinoma (HCC). We investigated the prognostic value of AFP levels in patients who achieved complete response (CR) to transarterial chemoembolization (TACE) for HCC.

Materials and Methods: Between 2005 and 2018, 890 patients with HCC who achieved a CR to TACE were recruited. An AFP responder was defined as a patient who showed elevated levels of AFP (>10 ng/mL) during TACE, but showed normalization or a >50% reduction in AFP levels after achieving a CR.

Results: Among the recruited patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection were treated. Before TACE, 305 (34.3%) patients had multiple tumors, 219 (24.6%) had a maximal tumor size >3 cm, and 22 (2.5%) had portal vein tumor thrombosis. The median AFP level after achieving a CR was 6.36 ng/mL. After a CR, 473 (53.1%) patients experienced recurrence, and 417 (46.9%) died [median progression-free survival (PFS) and overall survival (OS) of 16.3 and 62.8 months, respectively]. High AFP levels at CR (>20 ng/mL) were independently associated with a shorter PFS [hazard ratio (HR)=1.403] and OS (HR=1.284), together with tumor multiplicity at TACE (HR=1.518 and 1.666, respectively). AFP non-responders at CR (76.2%, n=359 of 471) showed a shorter PFS (median 10.5 months vs. 15.5 months, HR=1.375) and OS (median 41.4 months vs. 61.8 months, HR=1.424) than AFP responders (all p=0.001).

Conclusion: High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds clinical implications for detailed risk stratification upon achieving a CR after TACE.

Key Words: Carcinoma, hepatocellular; alpha-fetoprotein; prognosis; treatment outcome; transarterial chemoembolization

Received: June 11 2020 Revised: October 19, 2020 Accepted: November 12, 2020

Co-corresponding authors: Seung Up Kim, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: 82-2-2228-1930, Fax: 82-2-393-6884, E-mail: ksukorea@yuhs.ac; Dong Hyun Sinn, MD, PhD, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel: 82-2-3410-3049, Fax: 82-2-3410-6883, E-mail: dh.sinn@samsung.com

*Jae Seung Lee and Young Eun Chon contributed equally to this work.

The authors have no potential conflicts of interest to disclose.

© Copyright: Yonsei University College of Medicine 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

A significant portion of patients with intrahepatic hepatocellular carcinoma (HCC) are not suitable candidates for curative treatments, such as local ablation, surgical resection, and liver transplantation, due to decreased liver function, large tumor burden, and vascular invasion. The majority of these patients receive single or multiple rounds of transarterial chemoembolization (TACE), which takes advantage of the hypervascularized nature of HCC with increased arterial enhancement and rapid washout on imaging studies.

Recent studies have shown that response evaluation according to enhancement criteria, such as European Association for the Study of the Liver and modified response evaluation criteria in solid tumor (mRECIST) criteria, holds prognostic implications in patients with HCC, and a complete response (CR) has been found to be an independent predictor of overall survival (OS) among patients with inoperable HCC after TACE. Thus, to ensure better outcomes, achieving a CR after TACE according to enhancement criteria is most important in patients with HCC. However, CR achievement does not always guarantee total necrosis of the tumor or the absence of small intrahepatic metastases, and thus, a considerable portion of these patients experience recurrence that needs further treatments.

Serum alpha-fetoprotein (AFP) is a well-recognized biomarker that is overexpressed in the majority of human HCCs. AFP is usually low in adult serum because mature hepatocytes usually lose their ability to synthesize AFP. However, liver cancer cells can regain the ability to produce AFP, a phenomenon that is known to be correlated with tumor burden and poor differentiation. Previous studies have revealed that AFP levels are associated with prognosis after loco-regional treatment of HCC, and post-treatment changes in AFP levels are also known to be good prognostic factors for HCC, even after TACE. However, the prognostic value of AFP in patients who achieve a CR after TACE has not been investigated.

Therefore, we aimed to investigate whether changes in AFP levels between TACE and achieving a CR and absolute AFP levels upon achieving a CR have prognostic implications in patients with HCC.

MATERIALS AND METHODS

Patient eligibility

Patients who achieved a CR after one or more sessions of TACE as the first-line treatment were recruited using a retrospective review of patient databases at nine tertiary medical centers in Korea (Severance Hospital, Yonsei University College of Medicine; Samsung Medical Center, Sungkyunkwan University School of Medicine; Ewha Womans University College of Medicine; CHA Bundang Medical Center, CHA University; Ajou University School of Medicine; Inje University Haeundae Paik Hospital; Pusan National University Yangsan Hospital; Yeungnam University Medical Centre; and Kyungpook National University). The study population included patients treated for native HCC and recurrent HCC after curative resection.

The exclusion criteria were 1) under 19 years of age; 2) metastatic liver mass from other cancers; 3) co-existing extrahepatic tumor; 4) no measurement of AFP before TACE and at the time of confirming CR; 5) significant extrahepatic disease representing an imminent life threatening outcome; 6) uncontrolled medical comorbidity; 7) mortality of unknown cause that was not due to illness; 8) mortality that was absolutely due to procedure-related complications, rather than liver failure after TACE; 9) follow-up loss within 2 months after the TACE date after which the first CR was achieved; and 10) additional local therapies, such as radiofrequency ablation and intraarterial chemoinfusion, before the first CR.

The study protocol was in accordance with the 1975 Declaration of Helsinki guidelines. The need for written informed consent was waived because of the retrospective nature of this study. The Institutional Review Board, Yonsei University Health System, Severance Hospital approved the study procedure (IRB No. 4-2019-1272).

HCC diagnosis

HCC was diagnosed histologically or clinically according to the guidelines proposed by the Korea Liver Cancer Study Group. A positive finding for typical HCC on dynamic computed tomography or magnetic resonance imaging (MRI) was described as increased arterial enhancement followed by decreased enhancement, compared to the liver (washout), in the portal or equilibrium phases. Recurrent HCC was defined as the presence of newly appeared lesions strongly suspected for HCC rather than other malignancies in imaging studies after CR confirmation.

Barcelona Clinic Liver Cancer (BCLC) stage was classified based on the extent of the primary lesion, performance status according to each patient’s medical record, and portal vein tumor thrombosis. Since this study excluded patients with extrahepatic lesions, patients with BCLC stage C were classified according to portal vein tumor thrombosis and performance status.

Treatment modality

Before TACE, angiography of the superior mesenteric and hepatic arteries was performed to assess portal vein patency, vascular anatomy, and tumor vascularity. During TACE, a mixture of 5 mL of iodized oil contrast medium, lipiodol, and 25–75 mg of adriamycin was infused selectively at the level of a sub-segmental branch (if possible) or a segmental branch of the feeding arteries. Thereafter, embolization was performed using gelatin sponge particles. In cases of residual or recurrent viable tumor seen on liver dynamic computed tomography.
(LDCT) or MRI, sequential TACE was scheduled at 6- to 8-week intervals and on an ‘on-demand’ basis until CR achievement, provided that the patients’ clinical and laboratory findings permitted this and if there was no evidence of extrahepatic spread or major portal vein invasion without appearance of extrahepatic metastases, major portal vein invasion, or deterioration in the clinical status or laboratory values.

Assessment of treatment responses using mRECIST
The treatment responses were assessed 3–4 weeks after TACE sessions using LDCT or MRI. In cases where there was no viable portion of the tumor after TACE, patients underwent LDCT or MRI within 2–3 months until recurrence. Two or more independent radiologists in each institution analyzed the images to minimize the possibility of false categorizations.

The mRECIST guidelines, which define viable tumors according to the uptake of contrast material in the arterial phase of dynamic CT, were used in this study; tumors retaining iodized oil, as well as necrotic lesions without intratumoral arterial enhancement, were regarded as necrotized tumor foci. Up to two target lesions (selected in the order of the maximum baseline diameter to represent the entire tumor burden) in the liver were assessed using one-dimensional measurements according to previous investigations on the ‘optimal number of target lesions’ for the mRECIST guidelines on HCC treated with TACE. This study focused on the acquisition of a CR, defined by complete disappearance of viable lesions after TACE, and recurrence or progression, defined as a newly developed lesion from previously treated lesions or other sites.

Definitions
The time point of CR achievement after TACE was set as the baseline to investigate the prognostic value of AFP upon achieving a CR after TACE. The time point of TACE (at TACE) was defined as the time point of the last TACE just before obtaining a CR. An AFP responder was defined as a patient with elevated AFP levels (>10 ng/mL) at TACE, but with >50% reduction in AFP or AFP ≤10 ng/mL at CR. In contrast, AFP non-responders were defined as patients with AFP >10 ng/mL at TACE, ≤50% reduction in AFP, and elevated AFP >10 ng/mL at CR.

Statistical analysis
Considering the time interval between TACE and CR achievement, progression-free survival (PFS) was assessed from the date of achieving CR after TACE until the date of first recurrence or death. OS was calculated as the time interval between TACE and either death or final follow-up. PFS and OS were estimated by the Kaplan-Meier analysis, and survival differences between subgroups were assessed by log rank test. The Cox proportional hazards model was used for univariate and multivariate analyses of PFS and OS. All variables found to be significant in univariate analysis were included in the multivariate model. A p<0.05 was considered statistically significant, with a confidence interval (CI) of 95%. Statistical analyses were conducted using IBM SPSS Statistics software, version 25.0 (IBM Corp., Armonk, NY, USA).

RESULTS
Patient characteristics
From 2005 to 2018, a total of 890 patients with naïve or recurrent HCC after curative surgery who achieved a CR after single or multiple sessions of TACE as a front-line therapy were re-
viewed in this retrospective, multicenter, cohort study.

Baseline characteristics of the patients with a CR are summarized in Table 1. The median age of 695 (78.1%) male patients and 195 (21.9%) female patients was 61.4 [interquartile range (IQR), 55.0–69.4] years. Among all patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection were treated with TACE. Hepatitis B virus infection was identified in 621 (69.8%) patients, and 671 (75.4%) patients were diagnosed with liver cirrhosis. At TACE, 165 (18.6%) patients had intermediate and advanced stage HCC according to BCLC. Tumor multiplicity was identified in 305 (34.3%) patients, and the maximal tumor size was over 3 cm in 219 (24.6%) patients. A total of 53 (6.0%) patients had BCLC stage C HCC due to portal vein tumor thrombosis (n=22) and poor performance status (n=29).

**AFP levels and changes after CR achievement following TACE**

The median AFP level was 11.85 (IQR, 4.10–80.30) ng/mL, and elevated AFP levels (>10 ng/mL) were identified in 471 (52.9%) patients at TACE. The median AFP level at CR was 6.36 (IQR, 3.13–15.64) ng/mL, and the AFP value at CR was still elevated >10 ng/mL in 303 (34.0%) patients and >20 ng/mL in 196 (22.0%) patients. Of 471 patients with elevated AFP at TACE (>10 ng/mL), 112 (23.8%) patients were AFP non-responders (Tables 1 and 2).

**Prognosis after CR**

During the median follow-up period of 35.2 (IQR 20.5–67.5) months after TACE, 630 (70.8%) patients experienced HCC recurrence, and 417 (46.9%) patients died. Median PFS was 16.3 (IQR 7.9–41.6) months, and median OS was 62.8 (IQR 34.9–103.6). Among 471 patients with elevated AFP at TACE (>10 ng/mL), 112 (23.8%) patients were AFP non-responders (Tables 1 and 2).

Better outcomes in patients with low AFP values and AFP responders at CR

Among the study population, patients with an elevated AFP value >20 ng/mL at CR (n=196, 22.0%) showed significantly shorter PFS (median 11.2 months vs. 17.7 months, p<0.001) and OS (median 50.5 months vs. 70.2 months, p=0.003) than those with AFP below 20 ng/mL at CR. In the subgroup with an elevated AFP level >10 ng/mL at TACE (n=471), AFP responders showed a significantly longer PFS (median 15.5 months vs. 10.5 months, p=0.001) and OS (median 61.8 months vs. 41.4 months, p=0.001) than non-responders (Tables 2 and Fig. 1).

**Independent predictors of shorter PFS at CR**

Univariate analysis revealed that four variables were significantly associated with shorter PFS: BCLC stage B and C (vs. stage 0 and A), multiple tumors, low serum albumin, and an AFP value >20 ng/mL at CR (Supplementary Table 1, only online). Multivariate analysis showed that AFP >20 ng/mL at CR [hazard ratio (HR)=1.403] and tumor multiplicity (HR=1.518) were significantly associated with shorter PFS (Table 3). In a subgroup with an AFP level >10 ng/mL at TACE (n=471), AFP non-responders were independently associated with shorter PFS (HR=1.375), together with BCLC stage B/C (vs. 0/A, HR=1.377) and tumor multiplicity (HR=1.317) (Table 3 and Supplementary Table 1, only online).

**Independent predictors of shorter OS at CR**

An elevated AFP value (>20 ng/mL) at CR significantly predicted a shorter OS in univariate analysis with several other variables (Supplementary Table 2, only online). Multivariate analysis showed that AFP >20 ng/mL at CR (HR=1.310), tumor multiplicity at TACE (HR=1.614), and higher total bilirubin level at CR (HR=1.429) were significantly associated with shorter OS. Previous history of complete HCC resection was independently associated with longer OS (HR=0.713) (Table 4). In a subgroup with AFP >10 ng/mL at TACE, AFP non-responders

| Table 2. PFS and OS after TACE |
|--------------------------------|
| **Patient group** | **Survival** | **AFP ≤20 ng/mL at CR (n=694, 78.0%)** | **AFP >20 ng/mL at CR (n=196, 22.0%)** | **p value** |
| Overall patients (n=890) | | | | |
| PFS | Mean (95% CI) 34.4 (31.1–37.6) | 36.7 (32.8–40.5) | 25.4 (19.8–30.9) | <0.001 |
| | Median (IQR) 16.3 (7.9–41.6) | 17.7 (9.1–46.4) | 11.2 (6.5–26.9) | |
| OS | Mean (95% CI) 77.8 (73.0–82.5) | 80.4 (74.8–85.9) | 67.3 (58.6–75.9) | 0.003 |
| | Median (IQR) 62.8 (34.9–103.6) | 70.2 (38.4–105.8) | 50.5 (28.2–89.3) | |
| Patients with AFP >10 ng/mL at TACE (n=471) | | | | |
| PFS | Mean (95% CI) 30.1 (26.1–34.0) | 33.0 (28.2–37.7) | 18.3 (14.7–21.9) | 0.001 |
| | Median (IQR) 13.7 (7.3–36.5) | 15.5 (7.7–39.6) | 10.5 (6.7–20.8) | |
| OS | Mean (95% CI) 71.7 (65.9–77.4) | 76.3 (69.8–83.1) | 53.1 (45.4–60.9) | |
| | Median (IQR) 56.1 (31.5–95.6) | 61.8 (35.7–103.6) | 41.4 [26.1–75.8] | |

TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; CR, complete response; PFS, progression-free survival; OS, overall survival; CI, confidence interval; IQR, interquartile range.

*AFP responder: patients with AFP >10 ng/mL at TACE and a ≥50% reduction in AFP or AFP ≤10 ng/mL at CR, †AFP non-responder: patients with AFP >10 ng/mL at TACE and a ≤50% reduction in AFP and AFP >10 ng/mL at CR.
were independently associated with shorter OS (HR=1.406), together with tumor multiplicity at TACE (HR=1.463) and higher total bilirubin level at CR (HR=1.485). Previous HCC resection was still associated with longer OS (HR=0.761) in this subgroup (Table 4 and Supplementary Table 2, only online).

Subgroup analysis in patients with BCLC stage B HCC
When 112 patients with BCLC stage B HCC were selected (Supplementary Table 3, only online), patients with elevated AFP levels at CR (>20 ng/mL, n=80, 71.4%) showed shorter PFS (median 6.5 months vs. 13.5 months, \(p=0.002\)) and OS (median 28.2 months vs. 52.4 months, \(p=0.142\)), whereas AFP responders (n=42, 59.8%) did not have longer favorable PFS and OS, compared to non-responders (n=25, 37.3%, \(p=0.277\) and 0.882) (Supplementary Table 4, only online). Multivariate analysis showed that high AFP at CR (>20 ng/mL) was independently associated only with shorter PFS (HR=2.287, \(p<0.001\)) (Supplementary Tables 5 and 6 only online).

**DISCUSSION**
In this study, we evaluated whether AFP levels at CR achievement after TACE have prognostic value, based on the fact that...
not all patients who achieve radiological CR show AFP levels in the normal range. To this aim, we retrospectively analyzed 890 patients with HCC who achieved CR after TACE. Compared with previous studies that recruited mostly HCC patients with elevated AFP levels,16,17,20-24 our study population had relatively small tumors (median 2.0 cm) with mostly BCLC stage 0 and A tumors (81.4%), which might be associated with the higher rate of CR achievement after TACE. In addition, among patients with elevated AFP levels at TACE, 359 (76.2%) showed AFP response, which is similar or higher to the results from previous studies.20-24 In multivariate analysis, patients with elevated AFP levels,16,17,19,20 our study population had relapsed with previous studies that recruited mostly HCC patients with elevated AFP levels.16,17,20,26-32 In the present study, although the median AFP level at CR was higher than their counterparts. However, this definition might have some disadvantage in that it is difficult to apply directly to patients with low baseline AFP levels, and the effect of minor AFP changes on prognosis could be ignored. Therefore, we evaluated the impact of AFP normalization as an additional definition of AFP response. In our study, AFP response was defined not only as a 50% reduction in AFP levels from baseline, but also as its normalization (<10 ng/mL) at CR achievement. Similar with previous studies, using this definition, we found that patients with an AFP response showed better outcomes of prolonged PFS (median 15.5 months vs. 10.5 months) and OS (median 61.8 months vs. 41.4 months), compared to patients with no AFP response. An unfavorable AFP response might represent insufficient tumor necrosis by hypoxic damage through TACE more sensitively than post-treatment imaging studies, especially when imaging studies cannot provide any

| Table 3. Multivariate Analysis to Identify Independent Predictors for Shorter Progression-Free Survival after Achieving a CR after TACE |
|-----------------|-----------------|-----------------|-----------------|
| Variables       | Univariate p value | Multivariate Hazard ratio (95% CI) |
| All (n=890)     |                 |                    |                  |
| BCLC stage B/C vs. O/A | <0.001 | 1.252 (0.997–1.572) |
| Tumor multiplicity | <0.001 | 1.518 (1.262–1.827) |
| Serum albumin, g/dL | 0.004 | 0.875 (0.748–1.024) |
| AFP >20 ng/mL at CR | <0.001 | 1.403 (1.167–1.686) |
| Subgroup with AFP level >10 ng/mL at TACE (n=471) |                 |                    |                  |
| BCLC stage B/C vs. O/A | <0.001 | 1.377 (1.027–1.847) |
| Tumor multiplicity | <0.001 | 1.317 (1.022–1.697) |
| AFP non-responder* | 0.001 | 1.375 (1.077–1.756) |

CR, complete response; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.

*AFP non-responder: patients with AFP >10 ng/mL at TACE and a ≤50% reduction in AFP and AFP >10 ng/mL at CR.

| Table 4. Multivariate Analysis to Identify Independent Predictors for Shorter Overall Survival after Achieving a CR after TACE |
|-----------------|-----------------|-----------------|-----------------|
| Variables       | Univariate p value | Multivariate Hazard ratio (95% CI) |
| All (n=890)     |                 |                    |                  |
| Age >70 (yr)    | 0.016 | 1.222 (0.944–1.582) |
| Hepatitis B     | 0.010 | 0.844 (0.619–1.150) |
| Hepatitis C     | 0.020 | 1.023 (0.713–1.468) |
| Liver cirrhosis | 0.034 | 1.008 (0.794–1.279) |
| Recurrent HCC after complete resection | <0.001 | 0.713 (0.569–0.893) |
| BCLC stage B/C vs. O/A | 0.017 | 1.010 (0.762–1.340) |
| Tumor multiplicity | <0.001 | 1.666 (1.348–2.058) |
| Aspartate aminotransferase (IU/L) | 0.004 | 1.000 (0.999–1.001) |
| Serum albumin (g/dL) | <0.001 | 0.820 (0.658–1.021) |
| Total bilirubin (mg/dL) | <0.001 | 1.441 (1.268–1.638) |
| Prothrombin time (INR) | 0.001 | 1.269 (0.655–2.450) |
| AFP >20 ng/mL at CR | 0.003 | 1.284 (1.028–1.604) |
| Subgroup with AFP level >10 ng/mL at TACE (n=471) |                 |                    |                  |
| Recurrent HCC after complete resection | 0.001 | 0.761 (0.608–0.951) |
| BCLC stage B/C vs. O/A | 0.003 | 0.992 (0.896–1.415) |
| Tumor multiplicity | 0.003 | 1.463 (1.113–1.923) |
| Serum albumin (g/dL) | 0.003 | 0.924 (0.686–1.228) |
| Total bilirubin (mg/dL) | <0.001 | 1.485 (1.291–1.708) |
| Prothrombin time (INR) | 0.001 | 0.654 (0.320–2.046) |
| AFP non-responder* | 0.001 | 1.424 (1.070–1.895) |

CR, complete response; CI, confidence interval; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.

*AFP non-responder: patients with AFP >10 ng/mL at TACE and a ≤50% reduction in AFP and AFP >10 ng/mL at CR.
more information regarding tumor viability.\textsuperscript{33}

Third, along with AFP levels at CR and changes therein from baseline, tumor multiplicity was also independently associated with prognosis, in spite of CR achievement. To date, various tumor-staging systems have already incorporated tumor multiplicity, which has also been studied as a part of a prognostic scoring systems for TACE in several studies.\textsuperscript{32,34–36} In our study, the predictive value of tumor multiplicity at the time of TACE was maintained even after CR achievement. This might be due to a higher possibility for remnant viable tumors in the treated lesion, which were undetected using radiological assessment, or small intrahepatic tumors. In addition, BCLC stage B and C tended to be associated with shorter PFS, compared to BCLC stage 0-A (HR=1.252, \( p=0.053 \)).

Fourth, based on the results of our study, we cautiously suggest that further advanced surveillance strategies are required, even after CR achievement after TACE. To date, various scoring systems have been proposed to stratify patients with different prognoses after TACE. While it might be clinically infeasible to use complex scoring systems, using post-treatment AFP levels and changes therein as a biologic response surrogate after TACE, even after CR achievement, could be a simple and more intuitive way of aiding clinical decision-making. For patients with elevated AFP or poor AFP response after CR, surveillance using MRI,\textsuperscript{37} scheduled secondary angiography,\textsuperscript{19} and additional therapy, such as ablation or stereotactic radiotherapy, might be helpful for early detection of hidden lesions.\textsuperscript{38,39}

Although we focused on the time point of CR after one or several TACEs as our baseline, we collected additional information regarding the number of TACE sessions to achieve CR status. Most patients achieved CR through one (83.5\%) or two TACE sessions (14.0\%). Patients who achieved CR after multiple sessions of TACE had a significantly shorter OS than those with one TACE session (HR=1.730, \( p=0.002 \)), which was supported by a previous study showing that CR at first TACE was the most robust predictor for favorable OS.\textsuperscript{8} However, single or multiple TACE sessions did not influence PFS (\( p=0.177 \)), probably due to the significantly skewed distribution of the number of TACE sessions to achieve CR.

Several unresolved issues remain in our study. First, since most HCC diagnoses lacked histologic evaluations according to the current guidelines,\textsuperscript{1,4} the correlations between tumor differentiation and AFP levels were not identified.\textsuperscript{39} Second, the retrospective setting of the present study limited the evaluation of other potential risk factors, such as recurrent type of HCC (intrahepatic vs. intrahepatic and extrahepatic) and des-gamma carboxyprothrombin (DCP), which is another well-demonstrated serum marker for HCC prognosis. Although a previous study noted the poor performance of DCP response on prognosis after TACE,\textsuperscript{40} identifying its efficacy in patients with a CR may be of additional value for clinicians. Third, due to the retrospective nature of our study, it remains unclear why most patients with early HCC did not receive resection or ablation in our study. Old age, comorbidity, or preference to receive non-surgical treatment might be potential reasons for this. Indeed, in our institute, a significant proportion of patients with early stage HCC received TACE, instead of resection or ablation.\textsuperscript{2} Fourth, AFP and its response showed an insufficient association with outcomes in a subgroup with BCLC stage B, probably due to the skewed distribution of BCLC stages in our study. High AFP level was significantly associated with PFS among patients classified as BCLC stage B \( [n=112 (12.6\%)] \). However, AFP and its response were insufficiently associated with OS, while serum bilirubin still was found to influence the outcome. The significantly small distribution of this subgroup probably biased the association, especially in patients with AFP level \( >10 \text{ng/mL} \) at TACE \( [n=67 (7.5\%)] \). Fifth, this study could not evaluate the effect of disease progression after HCC relapse and subsequent treatments on patient prognosis. Finally, the influence of detailed technical variables, such as origin of the feeding vessel and procedure time, were not investigated.

In conclusion, high AFP and AFP non-responder were independently associated with poor outcomes after achieving a CR after TACE. Thus, assessment of AFP levels after achieving a CR after TACE might provide further detailed prognostication, even when radiological CR is achieved.

ACKNOWLEDGEMENTS

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2019R1A2C1070136).

AUTHOR CONTRIBUTIONS

Conceptualization: Jae Seung Lee, Young Eun Chon, Dong Hyun Sinn, and Seung Up Kim. Data curation: all authors. Formal analysis: Jae Seung Lee, Young Eun Chon, and Seung Up Kim. Funding acquisition: Seung Up Kim. Investigation: all authors. Methodology: Jae Seung Lee, Young Eun Chon, Dong Hyun Sinn, and Seung Up Kim. Project administration: Jae Seung Lee, Young Eun Chon, and Seung Up Kim. Resources: all authors. Supervision: Young Eun Chon and Seung Up Kim. Visualization: Jae Seung Lee, Dong Hyun Sinn, and Seung Up Kim. Writing—original draft: Jae Seung Lee and Seung Up Kim. Writing—review & editing: Jae Seung Lee, Young Eun Chon, Dong Hyun Sinn, and Seung Up Kim. Approval of final manuscript: all authors.

ORCID iDs

Jae Seung Lee  
https://orcid.org/0000-0002-2371-0967

Young Eun Chon  
https://orcid.org/0000-0002-7716-4850

Beom Kyung Kim  
https://orcid.org/0000-0002-5363-2496

Jun Yong Park  
https://orcid.org/0000-0001-6324-2224

Do Young Kim  
https://orcid.org/0000-0002-8327-3439

Sang Hoon Ahn  
https://orcid.org/0000-0002-3629-4624

Kwang-Hyub Han  
https://orcid.org/0000-0003-3960-6539

Wonseok Kang  
https://orcid.org/0000-0001-9578-8424

https://doi.org/10.3349/ymj.2021.62.1.12
REFERENCES

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.

2. Kim BK, Kim SJ, Park JY, Kim DY, Ahn SH, Park MS, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120–7.

3. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 2016;22:7–17.

4. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver 2015;9:267–317.

5. Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, et al. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol 2016;22:250–8.

6. Kim MN, Kim BK, Han KH, Kim SJ. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 2015;9:335–48.

7. Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1343–50.

8. Kim BK, Kim SJ, Kim KA, Chung YE, Kim MJ, Park MS, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol 2015;62:1304–10.

9. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9.

10. Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GV, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42–50.

11. Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 2013;82:e212–8.

12. Bannangloon K, Hongsaakul K, Tuabaee T, Piratisuth T. Safety margin of emobilized area can reduce local recurrence of hepatocellular carcinoma after plane-selective transarterial chemoembolization. Clin Mol Hepatol 2019;25:74–85.

13. Abbasi A, Bhutto AR, Butt N, Mumir SM. Correlation of serum alpha-fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc 2012;62:33–6.

14. Gao F, Zhu HK, Zhu YR, Shan QN, Ling Q, Wei XY, et al. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. Hepatobiliary Pancreat Dis Int 2016;15:371–7.

15. Kim DS, Lim TS, Jeon MY, Kim BK, Park JY, Kim DY, et al. Transarterial chemoembolization in treatment-naïve and recurrent hepatocellular carcinoma: a propensity-matched outcome analysis. Dig Dis Sci 2019;64:3660–8.

16. He C, Peng W, Liu X, Li C, Li JX, Wen TF. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2019;98:e16557.

17. Tian M, Zhang X, Huang G, Fan W, Li J, Zhang Y. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. Abdom Radiol (NY) 2019;44:3304–11.

18. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.

19. Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:e189–97.

20. Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013;13:5.

21. Liu G, Ouyang Q, Xiao F, Fan G, Yu J, Zhang C, et al. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. HPB (Oxford) 2019;21:107–13.

22. Zhang YQ, Jiang LJ, Wen J, Liu DM, Huang GH, Wang Y, et al. Comparison of α-fetoprotein criteria and modified response evaluation criteria in solid tumors for the prediction of overall survival of patients with hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 2018;29:1654–61.

23. Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, et al. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization. Oncология 2016;91:317–30.

24. He C, Zhang X, Li C, Peng W, Wen TF; Yan LN, et al. Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. Oncotar-
Prognostic Value of AFP at CR after TACE

get 2017;8:85599-611.

25. Fan LF, Zhao WC, Yang N, Yang GS. Alpha-fetoprotein: the predictor of microvascular invasion in small hepatocellular carcinoma and criterion for anatomic or non-anatomic hepatic resection. Hepatogastroenterology 2013;60:825-36.

26. Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90.

27. Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, et al. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2020;32:378-85.

28. Kim CG, Lee HW, Choi HJ, Lee JI, Lee HW, Kim SU, et al. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med 2019;8:5023-32.

29. Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, et al. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer 2019;19:363.

30. Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol 2016;51:344-53.

31. Paul SB, Sahu P, Sreenivas V, Nadda N, Gamanagatti SR, Nayak B, et al. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. Scand J Gastroenterol 2019;54:1132-7.

32. Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, et al. Prediction of survival among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 2020;72:198-212.

33. Mazure NM, Chauvet C, Bois-Joyeux B, Bernard MA, Nacer-Chérif H, Danan JL. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002;62:1158-65.

34. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.

35. Raoul JL, Sangro B, Forner A, Mazzaferrro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20.

36. Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 2016;36:100-7.

37. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:532-40.

38. Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol 2019;131:81-7.

39. Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, et al. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. Clin Mol Hepatol 2020;26:24-32.